Skip to main content

CCTG Connection



Published:
Category: Publications
Poster Presentation at the Society for Neuro-Oncology Annual Meeting
Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study
 
A CCTG poster presentation at the Society for Neuro-Oncology Annual Meeting, held November 19-23, 2025 in Honolulu. The abstract was then published in the journal Neuro-Oncology.
 
Patients with progressive IDH-mutant grade 2-3 glioma have limited therapeutic options.
Read More

Published:
Category: Publications
Publication: Post Hoc Analysis CRC6
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. This post hoc analysis used a clinically validated, tumor-informed assay to determine ctDNA status in 940 patients with stage III colon cancer and found that ctDNA negativity was highly associated with improved survival.
Read More

Published:
Category: Publications
Publication: Correlative CO.28
A new correlative study from CO.28 has been published: Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay
Read More

Published:
Category: Trials
Trial closure: CEC1

The CEC1 (EORTC 26053-22054) Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial has permanently closed.

Read More

Published:
Category: Trials
CCTG Trials in Development – Q4 2025
This quarter's most recent list of pending trials with general time frames to expected activation. Read More



Published:
Category: Group updates
Volunteer CRAs needed to join the CCTG CRA Executive

The Canadian Cancer Trials Group is actively seeking Clinical Research Associate (CRA) representatives from our Canadian member sites to sit on the CRA Executive Committee. 

Read More

Published:
Category: Publications
NCI MyeloMATCH Presentations at ASH 2025

NCI MyeloMATCH Presentations at ASH 2025

MyeloMATCH opened in mid-2024, and the first results from the trial are being presented at the 2025 ASH Annual Meeting (December 6-9, 2025; Orlando, FL). There will be an oral presentation and five posters at the meeting, please see the detailed information here >

Read More

Published:
Category: Publications
Publication: MAC4/MAC5 secondary analysis
MAC4 /MAC5 - Assessment of adjuvant endocrine therapy with ovarian function suppression by Breast Cancer Index
 
In this prognostic study of 1782 patients from a clinical trial, patients with tumors in which the expression of HOXB13 relative to IL17BR was low (BCI [H/I]–low) derived an absolute benefit of 6.6% in 12-year breast cancer–free interval from exemestane plus OFS vs tamoxifen plus OFS and those with BCI (H/I)–high tumors had a 6.3% absolute benefit, but with variable relative tre
Read More